Mette Kirstine Agger, as Managing Partner of Lundbeckfonden Ventures, invests in early-to-mid-stage biotechnology. See sector focus and contact routes.
Mette Kirstine Agger, as Managing Partner of Lundbeckfonden Ventures, invests in early-to-mid-stage biotechnology, health tech, and pharmaceutical companies—particularly those in clinical development—with typical check sizes of €3–€10 million. Her portfolio includes notable life science firms such as Notify Therapeutics, AFYX Therapeutics, NMD Pharma, Tiburio (developing treatments for rare tumours), and Sanifit Therapeutics (acquired by Vifor Pharma). Agger’s distinctive thesis emphasizes advancing neuroscience discoveries and therapies for rare genetic diseases, requiring founders to demonstrate robust clinical or translational data and a clear path to significant medical impact.
Details on this investor come from filing and round data held in the StartupFundraising directory, refreshed on ingest. Founders use profiles like this one to qualify fit and to shortlist investors in Copenhagen.
Investors like Mette Kirstine Agger · Full investor directory · Investor access · Company funding database